Breakdown | |||||
TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
951.17M | 965.26M | 1.22B | 1.34B | 1.21B | 897.02M | Gross Profit |
6.98M | 9.72M | 15.65M | -27.55M | 67.78M | 52.86M | EBIT |
-53.20M | -51.67M | -23.85M | -61.36M | 16.52M | -18.60M | EBITDA |
-24.63M | -26.76M | 2.60M | -12.75M | 61.89M | 51.15M | Net Income Common Stockholders |
-58.94M | -58.98M | -28.00M | -41.60M | 46.08M | -17.28M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
0.00 | 36.21M | 30.01M | 36.46M | 50.61M | 47.67M | Total Assets |
0.00 | 403.05M | 454.24M | 478.32M | 484.95M | 476.82M | Total Debt |
115.63M | 114.67M | 105.46M | 87.27M | 63.65M | 108.23M | Net Debt |
115.63M | 79.20M | 75.44M | 50.81M | 13.04M | 60.57M | Total Liabilities |
188.29M | 176.38M | 174.68M | 170.23M | 139.74M | 180.58M | Stockholders Equity |
213.92M | 225.06M | 279.56M | 308.09M | 345.21M | 296.24M |
Cash Flow | Free Cash Flow | ||||
-30.14M | -14.59M | -7.51M | -31.70M | 10.44M | 65.20M | Operating Cash Flow |
-23.18M | -3.52M | 22.02M | 6.05M | 26.82M | 71.78M | Investing Cash Flow |
-15.23M | -13.47M | -33.03M | -37.66M | 27.12M | 23.32M | Financing Cash Flow |
23.51M | 7.72M | 6.96M | 19.01M | -40.00M | -66.42M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
72 Outperform | $742.58M | 14.57 | 10.68% | ― | -18.36% | -13.81% | |
65 Neutral | $654.93M | 27.86 | 5.08% | 0.98% | -4.09% | -66.97% | |
52 Neutral | $304.11M | ― | -12.34% | ― | -19.82% | -34.91% | |
51 Neutral | $2.04B | -1.23 | -21.09% | 3.96% | 2.90% | -30.45% | |
50 Neutral | $294.66M | ― | -16.11% | ― | 145.38% | -22.02% | |
46 Neutral | $84.93M | ― | -24.43% | ― | -17.27% | -112.62% | |
43 Neutral | $120.85M | ― | 103.25% | 1.18% | -5.28% | 51.91% |
On May 19, 2025, Alto Ingredients, Inc. received a notification from Nasdaq indicating that its stock price had fallen below the minimum required for continued listing. The company has until November 15, 2025, to regain compliance by ensuring its stock price closes at or above $1.00 for at least 10 consecutive business days. If unsuccessful, Alto may qualify for an additional 180-day period to meet the requirements, potentially involving a reverse stock split. Failure to comply could result in delisting, though the company can appeal such a decision.
The most recent analyst rating on (ALTO) stock is a Buy with a $5.50 price target. To see the full list of analyst forecasts on Alto Ingredients stock, see the ALTO Stock Forecast page.
On March 17, 2025, Alto Ingredients, Inc. entered into a letter agreement with the Radoff/Torok Group, which includes provisions for board member nominations and standstill agreements. As part of this agreement, board members Douglas L. Kieta and Michael D. Kandris announced they would not stand for re-election at the 2025 Annual Meeting, impacting the company’s board composition and governance structure.